HRP20200580T1 - Novi spojevi - Google Patents

Novi spojevi Download PDF

Info

Publication number
HRP20200580T1
HRP20200580T1 HRP20200580TT HRP20200580T HRP20200580T1 HR P20200580 T1 HRP20200580 T1 HR P20200580T1 HR P20200580T T HRP20200580T T HR P20200580TT HR P20200580 T HRP20200580 T HR P20200580T HR P20200580 T1 HRP20200580 T1 HR P20200580T1
Authority
HR
Croatia
Prior art keywords
methyl
compound
trifluoromethyl
phenyl
pyrimidin
Prior art date
Application number
HRP20200580TT
Other languages
English (en)
Inventor
Gerard MP Giblin
David T Macpherson
David R Witty
Steven J STANWAY
Original Assignee
Convergence Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Convergence Pharmaceuticals Limited filed Critical Convergence Pharmaceuticals Limited
Publication of HRP20200580T1 publication Critical patent/HRP20200580T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (13)

1. Spoj koji je (5R)-7-Metil-2-[4-metil-6-[4-(trifluorometil)fenil]pirimidin-2-il]-1,7-diazaspiro[4.4]non-1-en-6-on ili (5S)-7-Metil-2-[4-metil-6-[4-(trifluorometil)fenil]pirimidin-2-il]-1,7-diazaspiro[4.4]non-1-en-6-on.
2. Spoj prema patentnom zahtjevu 1, naznačen time što je spoj (5S)-7-Metil-2-[4-metil-6-[4-(trifluorometil)fenil]pirimidin-2-il]-1,7-diazaspiro[4.4]non-1-en-6-on.
3. Postupak za pripravu spoja prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen time što obuhvaća provođenje reakcije zatvaranja prstena na (3R)-3-Amino-1-metil-3-[3-[4-metil-6-[4-(trifluorometil)fenil]pirimidin-2-il]prop-2-inil]pirolidin-2-onu ili (3S)-3-Amino-1-metil-3-[3-[4-metil-6-[4-(trifluorometil)fenil]pirimidin-2-il]prop-2-inil]pirolidin-2-onu.
4. Postupak kako je definirano u patentnom zahtjevu 3, naznačen time što se reakcija zatvaranja prstena provodi na (3S)-3-Amino-1-metil-3-[3-[4-metil-6-[4-(trifluorometil)fenil]pirimidin-2-il]prop-2-inil]pirolidin-2-onu.
5. Postupak za pripravu spoja s formulom (I): [image] ili njegove farmaceutski prihvatljive soli ili solvata, naznačen time što sadrži redukciju spoja prema patentnom zahtjevu 1 ili zahtjevu 2.
6. Postupak kako je definirano u patentnom zahtjevu 5, naznačen time što spoj s formulom (I) je spoj s formulom (Ia): [image] ili njegova farmaceutski prihvatljiva sol ili solvat.
7. Postupak kako je definirano u patentnom zahtjevu 5 ili zahtjevu 6, naznačen time što je spoj s formulom (I) hidrokloridna sol.
8. Postupak kako je definirano u patentnom zahtjevu 5 ili zahtjevu 6, naznačen time što je spoj s formulom (I) sol sumporne kiseline.
9. Postupak kako je definirano u patentnom zahtjevu 5 ili zahtjevu 6, naznačen time što je spoj s formulom (I) hidrat soli sumporne kiseline.
10. Postupak prema patentnom zahtjevu 3, naznačen time što provođenje reakcije zatvaranja prstena na (3R)-3-Amino-1-metil-3-[3-[4-metil-6-[4-(trifluorometil)fenil]pirimidin-2-il]prop-2-inil]pirolidin-2-onu sadrži dodavanje srebrovog trifluorometansulfonata u (3R)-3-Amino-1-metil-3-[3-[4-metil-6-[4-(trifluorometil)fenil]pirimidin-2-il]prop-2-inil]pirolidin-2-on.
11. Postupak prema patentnom zahtjevu 3, naznačen time što provođenje reakcije zatvaranja prstena na (3S)-3-Amino-1-metil-3-[3-[4-metil-6-[4-(trifluorometil)fenil]pirimidin-2-il]prop-2-inil]pirolidin-2-onu sadrži dodavanje srebrovog trifluorometansulfonata u (3S)-3-Amino-1-metil-3-[3-[4-metil-6-[4-(trifluorometil)fenil]pirimidin-2-il]prop-2-inil]pirolidin-2-on.
12. Postupak prema patentnom zahtjevu 5, naznačen time što je postupak za pripravu spoja s formulom (I) ili njegove farmaceutski prihvatljive soli.
13. Postupak prema patentnom zahtjevu 6, naznačen time što je postupak za pripravu spoja s formulom (Ia) ili njegove farmaceutski prihvatljive soli.
HRP20200580TT 2012-05-22 2020-04-06 Novi spojevi HRP20200580T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261650325P 2012-05-22 2012-05-22
GB201209015A GB201209015D0 (en) 2012-05-22 2012-05-22 Novel compounds
US201361773710P 2013-03-06 2013-03-06
EP16177700.8A EP3106464B1 (en) 2012-05-22 2013-05-22 Novel compounds

Publications (1)

Publication Number Publication Date
HRP20200580T1 true HRP20200580T1 (hr) 2020-10-02

Family

ID=46546493

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20161349TT HRP20161349T1 (hr) 2012-05-22 2016-10-17 7-metil-2-[4-metil-6-[4-(trifluorometil)-fenil]piramidin-2-il]-1,7-diazaspiro[4.4]nonan-6-on
HRP20200580TT HRP20200580T1 (hr) 2012-05-22 2020-04-06 Novi spojevi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20161349TT HRP20161349T1 (hr) 2012-05-22 2016-10-17 7-metil-2-[4-metil-6-[4-(trifluorometil)-fenil]piramidin-2-il]-1,7-diazaspiro[4.4]nonan-6-on

Country Status (28)

Country Link
US (7) US9309254B2 (hr)
EP (3) EP2861602B1 (hr)
JP (3) JP2015517562A (hr)
KR (2) KR102161101B1 (hr)
CN (2) CN107344942B (hr)
AU (3) AU2013265001B2 (hr)
BR (1) BR112014029280B1 (hr)
CA (1) CA2873956C (hr)
CY (2) CY1118274T1 (hr)
DK (2) DK3106464T3 (hr)
EA (1) EA025579B1 (hr)
ES (3) ES2602193T3 (hr)
GB (1) GB201209015D0 (hr)
HK (1) HK1209423A1 (hr)
HR (2) HRP20161349T1 (hr)
HU (2) HUE031664T2 (hr)
IL (4) IL235805A (hr)
IN (1) IN2014MN02393A (hr)
LT (2) LT3106464T (hr)
MX (1) MX355303B (hr)
PL (2) PL2861602T3 (hr)
PT (2) PT2861602T (hr)
RS (2) RS60368B1 (hr)
SG (2) SG11201407755UA (hr)
SI (2) SI2861602T1 (hr)
SM (1) SMT201600421B (hr)
WO (2) WO2013175205A1 (hr)
ZA (1) ZA201408253B (hr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
CA3074923A1 (en) * 2017-09-28 2019-04-04 Biogen Inc. Novel salts
MX2020003821A (es) 2017-10-10 2023-01-12 Biogen Inc Proceso de elaboración de espiroderivados.
WO2022133097A1 (en) * 2020-12-17 2022-06-23 Biogen Ma Inc. Synthesis of compounds that modulate use-dependent voltage-gated sodium channels

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005293A2 (en) * 2002-07-05 2004-01-15 Targacept, Inc. N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
GB0520578D0 (en) * 2005-10-10 2005-11-16 Glaxo Group Ltd Novel compounds
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
US8143306B2 (en) 2005-10-10 2012-03-27 Convergence Pharmaceuticals Limited Methods of treating bipolar disorders
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
WO2007042250A1 (en) 2005-10-10 2007-04-19 Glaxo Group Limited Prolinamide derivatives as sodium channel modulators
JP2009511599A (ja) * 2005-10-12 2009-03-19 バーテックス ファーマシューティカルズ インコーポレイテッド 電位依存性イオンチャネルの調整剤としてのビフェニル誘導体
US7998959B2 (en) * 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
CL2007002953A1 (es) 2006-10-12 2008-02-01 Xenon Pharmaceuticals Inc Compuestos derivados de espiro-oxindol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del dolor, cancer, prurito, hiperplasia prostatica benigna, hipercolesterolemia.
CN101522685A (zh) * 2006-10-12 2009-09-02 泽农医药公司 三环螺-吲哚酮衍生物及其作为治疗剂的用途
CN101641099A (zh) 2007-01-24 2010-02-03 葛兰素集团有限公司 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物
GB0701365D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0701366D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds
AR077252A1 (es) * 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US8759542B2 (en) 2009-09-14 2014-06-24 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide derivatives
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
TWI625046B (zh) * 2012-03-21 2018-05-21 內數位專利控股公司 在無線網路中行動站贊助方法及裝置
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
GB201209670D0 (en) 2012-05-31 2012-07-18 Convergence Pharmaceuticals Novel compounds

Also Published As

Publication number Publication date
GB201209015D0 (en) 2012-07-04
WO2013175206A1 (en) 2013-11-28
AU2013265001B2 (en) 2016-12-01
EP3106464A1 (en) 2016-12-21
EA025579B1 (ru) 2017-01-30
PT2861602T (pt) 2016-11-14
CA2873956C (en) 2021-03-23
PL3106464T3 (pl) 2020-11-16
IL252033B (en) 2019-12-31
US20170304303A1 (en) 2017-10-26
EA201492169A1 (ru) 2015-04-30
RS60368B1 (sr) 2020-07-31
ES2602193T3 (es) 2017-02-20
AU2013265001A1 (en) 2014-12-18
JP6169687B2 (ja) 2017-07-26
CN104640867B (zh) 2017-07-21
BR112014029280B1 (pt) 2022-10-04
US20200289508A1 (en) 2020-09-17
CN107344942A (zh) 2017-11-14
US10010551B2 (en) 2018-07-03
ES2782088T3 (es) 2020-09-10
EP2861594B1 (en) 2016-08-24
IL271330B (en) 2021-02-28
AU2018201653B2 (en) 2019-05-02
SG10201703527WA (en) 2017-06-29
RS55415B1 (sr) 2017-04-28
US20150119404A1 (en) 2015-04-30
US10485801B2 (en) 2019-11-26
SMT201600421B (it) 2017-01-10
US20160184306A1 (en) 2016-06-30
HRP20161349T1 (hr) 2017-01-27
US20180360833A1 (en) 2018-12-20
IL271330A (en) 2020-01-30
US9309254B2 (en) 2016-04-12
PL2861602T3 (pl) 2017-05-31
SI3106464T1 (sl) 2020-12-31
HUE049445T2 (hu) 2020-09-28
HK1209423A1 (en) 2016-04-01
US9376445B2 (en) 2016-06-28
DK3106464T3 (da) 2020-03-23
US20160263115A1 (en) 2016-09-15
CN107344942B (zh) 2020-09-25
DK2861602T3 (en) 2016-11-28
WO2013175205A1 (en) 2013-11-28
PT3106464T (pt) 2020-04-03
ES2602308T3 (es) 2017-02-20
ZA201408253B (en) 2015-12-23
KR102161101B1 (ko) 2020-10-20
AU2018201653A1 (en) 2018-03-29
SI2861602T1 (sl) 2017-03-31
IL280595A (en) 2021-03-25
JP2015517562A (ja) 2015-06-22
JP2017206534A (ja) 2017-11-24
US20150166551A1 (en) 2015-06-18
IL235805A0 (en) 2015-02-01
IN2014MN02393A (hr) 2015-08-21
KR20200113027A (ko) 2020-10-05
IL252033A0 (en) 2017-06-29
JP6378404B2 (ja) 2018-08-22
CA2873956A1 (en) 2013-11-28
MX355303B (es) 2018-04-12
CY1118274T1 (el) 2017-06-28
JP2015517561A (ja) 2015-06-22
IL235805A (en) 2017-05-29
SG11201407755UA (en) 2014-12-30
MX2014014274A (es) 2015-06-17
HUE031664T2 (en) 2017-07-28
CY1123044T1 (el) 2021-10-29
AU2017201421B2 (en) 2017-12-07
EP2861602A1 (en) 2015-04-22
EP2861602B1 (en) 2016-08-10
US9737536B2 (en) 2017-08-22
EP2861594A1 (en) 2015-04-22
AU2017201421A1 (en) 2017-03-23
BR112014029280A2 (pt) 2017-06-27
EP3106464B1 (en) 2020-01-08
LT2861602T (lt) 2016-11-10
KR20150023401A (ko) 2015-03-05
LT3106464T (lt) 2020-04-10
CN104640867A (zh) 2015-05-20

Similar Documents

Publication Publication Date Title
HRP20200580T1 (hr) Novi spojevi
PE20171057A1 (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
FR2998297B1 (fr) Procede de preparation de sel d'imides contenant un groupement fluorosulfonyle
ZA201500728B (en) Crystalline forms of 1-(5'-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)4,5-dihydroisoxazol-3-yl)-3'h-spiro[azetidine-3,1'-isobenzofuran]-1-yl)-2-(methylsulfonyl)ethanone
IL229815A (en) Process for Preparing Transocyclic Trans - 7 - Oxo - 6 - (Sulfooxy) - 1, 6 - Diazabicyclo [1,2,3] Octane - 2 - Carboxamide and their Salts
IL244239B (en) Process for the preparation of (s2,r5)-6-(benzyl/allyl)oxy-7-oxo-6,1-diazabicyclo[1.2.3]octane-2-carboxylic acid, and also its esters and salts
MA35452B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
ZA201209297B (en) 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
SI3004090T1 (en) Chemical compounds
GEP201706774B (en) Heterocyclyl compounds
EA201791873A1 (ru) Полиморф ингибиторов syk
ZA201306719B (en) 3,4-dihydro-pyrrolo[1,2-a]pyrazin-1-ylamine derivatives useful as inhibitors of beta-secretase (bace)
EP2484673A3 (en) A process for the resolution of (R,S)-nicotine
WO2013186792A3 (en) Process for preparation of azilsartan medoxomil and its salts
HK1202237A1 (zh) -二氯- -苯並 咪唑- -基 -吡唑- -羧酸的葡甲胺鹽製劑
EA201400182A1 (ru) Производные пиридин-2(1н)-она в качестве ингибиторов jak
PE20142244A1 (es) Inhibidores de pirazolopirimidinilo de enzima activadora de ubiquitina
DK3310760T3 (da) Krystallinsk L-argininsalt af (R)-2-(7-(4-cyclopentyl-3-(trifluormethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)eddikesyre til anvendelse ved S1P1-receptor-associerede lidelser
JP2015500842A5 (hr)
PT3077390T (pt) Forma de sal cristalino de (s)-(2-(6-cloro-7-metil-1hbenzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona como antagonista do recetor de orexina
WO2016135747A3 (en) Process for the preparation of amorphous (1s)-1,5-anhvdro-1-[3-[[5-(4 fluorophennyl)-2-thienyl]methvl]-4-methylphenyl]-d-glucitol and its polymorphs thereof
WO2013183035A3 (en) Amides of 2-amino-4-arylthiazole compounds and their salts
FR2991323B1 (fr) Sel d'anions bicycliques aromatiques pour batteries li-ion
EP2611806A4 (en) HETEROCYCLIC COMPOUNDS ENRICHED IN DEUTERIUM AS INHIBITORS OF KINASES
MX2015011722A (es) Proceso para la preparacion de (2s, 5r)-7-oxo-6-sulfooxi-2-[((3r)- piperidin-3-carbonil)carbonil hidrazino]-1,6-diaza-biciclo[3.2.1] octano.